Related references
Note: Only part of the references are listed.Impact of Y143 HIV-1 Integrase Mutations on Resistance to Raltegravir In Vitro and In Vivo
Olivier Delelis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort
Linda Wittkop et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug
Marc Wirden et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
A combined genotypic and phenotypic human immunodeficiency virus type 1 recombinant virus assay for the reverse transcriptase and integrase genes
Kurt Van Baelen et al.
JOURNAL OF VIROLOGICAL METHODS (2009)
Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways
Signe Fransen et al.
JOURNAL OF VIROLOGY (2009)
The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation
Olivier Delelis et al.
NUCLEIC ACIDS RESEARCH (2009)
A conventional LC-MS method developed for the determination of plasma raltegravir concentrations
Masaaki Takahashi et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2008)
Antiretroviral drug resistance testing in adult HIV-1 infection:: 2008 recommendations of an International AIDS Society-USA panel
Martin S. Hirsch et al.
CLINICAL INFECTIOUS DISEASES (2008)
Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors
Olivia Goethals et al.
JOURNAL OF VIROLOGY (2008)
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
David A. Cooper et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Raltegravir with optimized background therapy for resistant HIV-1 infection
Roy T. Steigbigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Broad Antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)
Kazuya Shimura et al.
JOURNAL OF VIROLOGY (2008)
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial
Beatriz Grinsztejn et al.
LANCET (2007)
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals
Martin Markowitz et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Integrase inhibitors to treat HIV/AIDS
Y Pommier et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Styrylquinolines, integrase inhibitors acting prior to integration:: a new mechanism of action for anti-integrase agents
S Bonnenfant et al.
JOURNAL OF VIROLOGY (2004)
New class of HIV integrase inhibitors that block viral replication in cell culture
C Pannecouque et al.
CURRENT BIOLOGY (2002)
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells
DJ Hazuda et al.
SCIENCE (2000)
Share Paper
